Upstate Active Clinical Trials

Study Title:

S2402-PERIOPERATIVE VERSUS ADJUVANT SYSTEMIC THERAPY IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER – PROSPECT LUNG

What is the purpose of the study? (in Layman's terms, please describe the study)

To compare the 3-year real-world event-free survival (rwEFS) rate and overall survival (OS) between perioperative and adjuvant immunotherapy-based treatment for patients with resectable non-small cell lung cancer (dual endpoints).

Upstate Institutional Review Board (IRB) Number:

2274823

Study/Protocol ID:

S2402

Study Phase:

IIA to IIIB NSCLC (p

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

What is involved if I participate?

• How long is the study?
  10Years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  Laboratory and clinical parameters during treatment are to be followed using individual institutional guidelines and the best clinical judgment of the responsible physician. It is expected that patients on this study will be cared for by physicians experienced in the treatment and supportive care of patients on this trial.

Where will the study take place?

Cancer center/Verona cancer center/Oswego cancer center / community cancer center

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT06632327

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Raneem Alarawi
Phone: 315-464-6074
Email: [email protected]

Return to Previous Page || Search Again